Annual CFF
$182.77 M
-$184.81 M-50.28%
December 31, 2024
Summary
- As of March 12, 2025, PHAT annual cash flow from financing activities is $182.77 million, with the most recent change of -$184.81 million (-50.28%) on December 31, 2024.
- During the last 3 years, PHAT annual CFF has risen by +$138.07 million (+308.82%).
- PHAT annual CFF is now -50.28% below its all-time high of $367.58 million, reached on December 31, 2023.
Performance
PHAT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$26.05 M
-$96.01 M-78.66%
December 31, 2024
Summary
- As of March 12, 2025, PHAT quarterly cash flow from financing activities is $26.05 million, with the most recent change of -$96.01 million (-78.66%) on December 31, 2024.
- Over the past year, PHAT quarterly CFF has stayed the same.
- PHAT quarterly CFF is now -87.71% below its all-time high of $211.99 million, reached on December 31, 2023.
Performance
PHAT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$182.77 M
-$185.95 M-50.43%
December 31, 2024
Summary
- As of March 12, 2025, PHAT TTM cash flow from financing activities is $182.77 million, with the most recent change of -$185.95 million (-50.43%) on December 31, 2024.
- Over the past year, PHAT TTM CFF has stayed the same.
- PHAT TTM CFF is now -50.43% below its all-time high of $368.72 million, reached on September 30, 2024.
Performance
PHAT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PHAT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -50.3% | 0.0% | 0.0% |
| 3 y3 years | +308.8% | +100.0% | +52.3% |
| 5 y5 years | -40.0% | +100.0% | +52.3% |
PHAT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -50.3% | +308.8% | -87.7% | -100.0% | -50.4% | +312.6% |
| 5 y | 5-year | -50.3% | +308.8% | -87.7% | -100.0% | -50.4% | +312.6% |
| alltime | all time | -50.3% | +9509.6% | -87.7% | +2105.1% | -50.4% | -100.0% |
Phathom Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $182.77 M(-50.3%) | $26.05 M(-78.7%) | $182.77 M(-50.4%) |
| Sep 2024 | - | $122.06 M(+392.7%) | $368.72 M(+49.5%) |
| Jun 2024 | - | $24.77 M(+150.2%) | $246.68 M(-32.1%) |
| Mar 2024 | - | $9.90 M(-95.3%) | $363.41 M(-1.1%) |
| Dec 2023 | $367.58 M(+206.2%) | $211.99 M(>+9900.0%) | $367.58 M(+136.3%) |
| Sep 2023 | - | $13.00 K(-100.0%) | $155.59 M(-13.6%) |
| Jun 2023 | - | $141.50 M(+905.6%) | $180.17 M(+34.3%) |
| Mar 2023 | - | $14.07 M(>+9900.0%) | $134.11 M(+11.7%) |
| Dec 2022 | $120.04 M(+168.5%) | $0.00(-100.0%) | $120.04 M(-0.1%) |
| Sep 2022 | - | $24.60 M(-74.2%) | $120.20 M(-13.9%) |
| Jun 2022 | - | $95.45 M(>+9900.0%) | $139.64 M(+215.2%) |
| Mar 2022 | - | $0.00(-100.0%) | $44.30 M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $44.71 M(-60.9%) | $163.00 K(-99.6%) | $44.71 M(-66.6%) |
| Sep 2021 | - | $44.03 M(>+9900.0%) | $134.00 M(+48.9%) |
| Jun 2021 | - | $104.00 K(-74.8%) | $89.97 M(+0.1%) |
| Mar 2021 | - | $412.00 K(-99.5%) | $89.87 M(-21.5%) |
| Dec 2020 | $114.46 M(-62.4%) | $89.46 M(>+9900.0%) | $114.46 M(-47.4%) |
| Sep 2020 | - | $0.00(0.0%) | $217.77 M(+0.6%) |
| Jun 2020 | - | $0.00(-100.0%) | $216.47 M(-34.3%) |
| Mar 2020 | - | $25.00 M(-87.0%) | $329.65 M(+8.2%) |
| Dec 2019 | $304.65 M(>+9900.0%) | $192.77 M(<-9900.0%) | $304.65 M(+172.3%) |
| Sep 2019 | - | -$1.30 M(-101.1%) | $111.88 M(-1.1%) |
| Jun 2019 | - | $113.17 M(>+9900.0%) | $113.17 M(>+9900.0%) |
| Mar 2019 | - | $0.00 | $0.00 |
| Dec 2018 | $1.90 M | - | - |
FAQ
- What is Phathom Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals annual CFF year-on-year change?
- What is Phathom Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals quarterly CFF year-on-year change?
- What is Phathom Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals TTM CFF year-on-year change?
What is Phathom Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of PHAT is $182.77 M
What is the all time high annual CFF for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high annual cash flow from financing activities is $367.58 M
What is Phathom Pharmaceuticals annual CFF year-on-year change?
Over the past year, PHAT annual cash flow from financing activities has changed by -$184.81 M (-50.28%)
What is Phathom Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of PHAT is $26.05 M
What is the all time high quarterly CFF for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high quarterly cash flow from financing activities is $211.99 M
What is Phathom Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, PHAT quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Phathom Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of PHAT is $182.77 M
What is the all time high TTM CFF for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high TTM cash flow from financing activities is $368.72 M
What is Phathom Pharmaceuticals TTM CFF year-on-year change?
Over the past year, PHAT TTM cash flow from financing activities has changed by $0.00 (0.00%)